About
Dorsagliptin – is an innovative drug developed by the Chinese company Hua Medicine. Unlike most antidiabetic drugs, it does not simply lower blood sugar levels, but restores the body's natural glucose balance.
Clinical studies have shown that in many patients, the disease can enter a stage of sustained remission — blood sugar levels return to normal and remain stable even after discontinuing the drug.
How it works
The diagram shows how dorzagliatin activates glucokinase in the liver and pancreas. This is a key enzyme whose function is impaired in type 2 diabetes.
  • Blood Sugar Control
    Lowers blood sugar levels, keeping them within the normal range.
  • β-Cell Support
    Improves pancreatic function, preserving the cells that produce insulin.
  • Dual Action
    Acts simultaneously in the liver and pancreas, helping store glycogen and regulate hormones.
Clinical Research
  • Type 2 Diabetes Remission in the DREAM Research
    In the DREAM study (phase III, observational), patients who completed a course of dorzagliatin therapy maintained normal blood sugar levels even without continuing treatment. After 52 weeks, 65.2% of participants achieved sustained remission. This means their HbA1c levels remained within the target range (<7%) without taking other medications.
  • Large SEED Research
    • As early as 8 weeks, many patients’ blood sugar levels reached the target range.
    • After 24 weeks, patients taking dorzagliatin had their HbA1c reduced by nearly 1.1%, compared to only 0.5% in the placebo group.
    • Every third patient on dorzagliatin achieved levels below 7% (considered good diabetes control).
  • Uniqueness
  • The first and only glucokinase activator approved.
  • Competitors (Merck, Amgen, Pfizer) halted development at early stages.
  • Dorzagliatin remains the only drug to successfully complete phase III trials.
Minimal risk of hypoglycemia
— low blood sugar episodes were extremely rare (<1%), with no severe cases recorded.
Good tolerability
— большинство побочных эффектов были лёгкой степени и не требовали отмены препарата.
Weight gain
Does not cause weight gain and does not worsen liver markers, which differentiates it from many other glucose-lowering drugs.
Get More Information
Fill out your details below and we will contact you.
You agree to our Terms and Conditions